Peritoneal dialysis and in-centre haemodialysis: A cost-utility analysis from a UK payer perspective

Applied Health Economics and Health Policy

Volumn 12, Issue 4, 2014, Pages 409-420

  Treharne, Catrin ^a   Liu, Frank Xiaoqing ^b   Arici, Murat ^c   Crowe, Lydia ^a   Farooqui, Usman ^c  

^a Decision Resources Group   (United Kingdom)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Baxter Healthcare   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IN CENTER HEMODIALYSIS; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL; UNITED KINGDOM; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; KIDNEY FAILURE, CHRONIC; OUTPATIENT DEPARTMENT; PROBABILITY; QUALITY OF LIFE; STATISTICAL MODEL;

AMBULATORY CARE FACILITIES; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEALTH EXPENDITURES; HUMANS; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MODELS, ECONOMETRIC; PERITONEAL DIALYSIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE;

EID: 84904969254     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0108-7     Document Type: Article

References (62)

1. Ayodele OE, Alebiosu CO. Burden of chronic kidney disease: an international perspective. Adv Chronic Kidney Dis. 2010;17(3):215-24.
2. Fresenius Medical Care. ESRD patients in 2012. A global perspective. Available from: http://www.vision-fmc.com/files/pdf-2/ESRD-Patients-2012.pdf. Accessed Aug 2013.
3. Shaw C. UK Renal Registry 16th Annual Report: Chapter 2 UK RRT Prevalence in 2012: National and Centre-specific Analyses. 2013. Available from: http://www.renalreg.com/Report-Area/Report%202013/02-Chap-02.pdf. Accessed Jan 2014.
4. Gilg J. UK Renal Registry 16th Annual Report: Chapter 1 UK Renal Replacement Therapy Incidence in 2012: National and Centre-specific Analyses. 2013. Available from: http://www.renalreg.com/Report-Area/Report%202013/01-Chap- 01.pdf. Accessed Jan 2014.
5. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(Suppl 3):iii73-80.
6. National Institute for Health and Clinical Excellence (NICE). Peritoneal dialysis (Clinical guidelines, CG125). Peritoneal dialysis in the treatment of stage 5 chronic kidney disease. Available from http://www.nice.org.uk/nicemedia/ live/13524/55517/55517.pdf. Accessed Apr 2013.
7. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis. 2004;43(5):891-9. (Pubitemid 38529627)
8. Brady M, O'Donoghue D. Back to the future: changes in the dialysis delivery model in the UK. Perit Dial Int. 2011;31(Suppl 2):S63-72.
9. Castledine CI, Caskey FJ, Tomson CR, Ansell D. Trends in renal replacement therapy and changes in peritoneal dialysis utilization in the United kingdom. Perit Dial Int. 2011;31(Suppl 2):S53-7.
10. National Institute for Health and Clinical Excellence (NICE). Cost effectiveness of peritoneal dialysis provision. Available from: http://www.nice.org.uk/nicemedia/live/12347/52540/52540.pdf. Accessed Apr 2013.
11. National Health Service (NHS) Improvement. E-QIPP. Available from http://www.improvement.nhs.uk/Default.aspx?alias=www.improvement.nhs.uk/qipp. Accessed Apr 2013.
12. National Institute for Health and Clinical Excellence (NICE). Kidney disease: peritoneal dialysis. Costing report. Implementing NICE guidance. July 2011. Available from: www.nice.org.uk/nicemedia/live/13524/55549/55549.pdf. Accessed Nov 2013.
13. HM Treasury. The green book. Appraisal and evaluation in central government; 2011.
14. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409. (Pubitemid 28140699)
15. Kirby L, Vale L. Dialysis for end-stage renal disease. Determining a cost-effective approach. Int J Technol Assess Health Care. 2001;17(2):181-9. (Pubitemid 32574956)
16. NHS purchasing and supply agency. Economic Report Home haemodialysis. CEP10063; 2010.
17. European Renal Association (ERA) and European Dialysis and Transplant Association (EDTA). ERA-EDTA Registry Annual Report 2009. Available from http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2009.pdf. Accessed Mar 2013.
18. US Renal Data System. USRDS 2013 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Incidence, prevalence, patient characteristics and treatment modalities. Available from: http://www.usrds.org/2013/pdf/v2-ch1-13.pdf. Accessed Dec 2013.
19. European Renal Association (ERA) and European Dialysis and Transplant Association (EDTA). ERA-EDTA Registry Annual Report 2011. Available from: http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2011.pdf. Accessed Nov 2013.
20. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna; 2012.
21. Chiu YW, Jiwakanon S, Lukowsky L, Duong U, Kalantar-Zadeh K, Mehrotra R. An update on the comparisons of mortality outcomes of hemodialysis and peritoneal dialysis patients. Semin Nephrol. 2011;31(2):152-8.
22. NHS Blood and Transplant. Organ Donation and Transplantation: Activity Report 2012/2013. Available from: http://www.organdonation.nhs.uk/statistics/ transplant-activity-report/current-activity-reports/ukt/activity-report-2012-13. pdf. Accessed Jan 2014.
23. Brown EA, Johansson L, Farrington K, Gallagher H, Sensky T, Gordon F, et al. Broadening options for long-term dialysis in the elderly (BOLDE): differences in quality of life on peritoneal dialysis compared to haemodialysis for older patients. Nephrol Dial Transplant. 2010;25(11):3755-63.
24. Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. JAMA. 2004;291(6):697-703. (Pubitemid 38543789)
25. Goodlad C, Brown E. The role of peritoneal dialysis in modern renal replacement therapy. Postgrad Med J. 1056;2013(89):584-90.
26. McLaughlin K, Manns B, Mortis G, Hons R, Taub K. Why patients with ESRD do not select self-care dialysis as a treatment option. Am J Kidney Dis. 2003;41(2):380-5. (Pubitemid 36152457)
27. Juergensen E, Wuerth D, Finkelstein SH, Juergensen PH, Bekui A, Finkelstein FO. Hemodialysis and peritoneal dialysis: patients' assessment of their satisfaction with therapy and the impact of the therapy on their lives. Clin J Am Soc Nephrol. 2006;1(6):1191-6.
28. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008;11(4):733-41. (Pubitemid 352032818)
29. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44(3):215-32. (Pubitemid 28345184)
30. Lafrance JP, Rahme E, Iqbal S, Elftouh N, Vallee M, Laurin LP, et al. Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis. Clin J Am Soc Nephrol. 2012;7(10):1598-605.
31. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-300.
32. Arora P, Kausz AT, Obrador GT, Ruthazer R, Khan S, Jenuleson CS, et al. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol. 2000;11(4):740-6. (Pubitemid 30171883)
33. Xue H, Ix JH, Wang W, Brunelli SM, Lazarus M, Hakim R, et al. Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications. Am J Kidney Dis. 2013;61(1):123-30.
34. Department of Health. Payment by results 2013-2014. Available from: https://www.gov.uk/government/collections/payment-by-results-2013-14. Accessed Jan 2014.
35. British Medical Association. British National Formulary (BNF), No. 67. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2014.
36. Rao A, Gilg J, Williams A. UK Renal Registry 15th Annual Report (December 2012): Chapter 6: Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2011: national and centre-specific analyses. Available from: http://www.renalreg.com/Report-Area/Report%202012/Chapter-6.pdf Accessed Jan 2014.
37. Department of Health. NHS Reference costs 2011-2012. Available from: http://www.dh.gov.uk/health/2012/11/2011-12-referencecosts/Accessed Jan 2014.
38. Department for Work and Pensions. Z1 - Recovery of benefits and or lump sum payments and NHS charges: Procedures for liaison with the Compensation Recovery Unit; 2013.
39. Department of Health. NHS Reference costs 2009-2010. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123459. Accessed Jan 2014.
40. The NHS Information Centre. National Kidney Care Audit. Patient Transport Survey 2010; 2011.
41. NHS Kidney Care. Developing robust reference costs for kidney transplantation in adults - Update; 2011.
42. Department of Health. NHS Reference costs 2012-2013. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013. Accessed Feb 2014.
43. Gonzalez-Perez JG, Vale L, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. Int J Technol Assess Health Care. 2005;21(1):32-9. (Pubitemid 40229366)
44. Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technology Assessment 2003. Available from: http://www.journalslibrary.nihr.ac.uk/hta/volume-7/issue-2. Accessed 16 Sept 2013.
45. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant. 2011;26(9):2988-95.
46. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003;64(3):1004-11. (Pubitemid 37013836)
47. National Institute for Health and Clinical Excellence (NICE). Cost effectiveness of peritoneal dialysis provision. Available from http://www.nice.org.uk/nicemedia/live/12347/52540/52540.pdf. Accessed Apr 2013.
48. Lukowsky LR, Mehrotra R, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin J Am Soc Nephrol. 2013;8(4):619-28.
49. Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis. 2011;18(6):428-32.
50. Villa G, Fernandez-Ortiz L, Cuervo J, Rebollo P, Selgas R, Gonzalez T, et al. Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit Dial Int. 2012;32(2):192-9.
51. Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, et al. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology (Carlton). 2009;14(1):123-32.
52. Neil N, Walker DR, Sesso R, Blackburn JC, Tschosik EA, Sciaraffia V, et al. Gaining efficiencies: resources and demand for dialysis around the globe. Value Health. 2009;12(1):73-9.
53. Department of Health. Making the NHS more efficient and less bureaucratic (March 2013). Available from https://www.gov.uk/government/policies/making-the- nhs-more-efficient-and-lessbureaucratic. Accessed Apr 2013.
54. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis. 2009;53(2):290-7.
55. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis. Kidney Int. 2006;69(5):798-805.
56. Rocco MV, Lockridge RS Jr, Beck GJ, Eggers PW, Gassman JJ, Greene T, et al. The effects of frequent nocturnal home hemodialysis: the frequent hemodialysis network nocturnal trial. Kidney Int. 2011;80(10):1080-91.
57. Gilg J, Castledine C, Fogarty D, Feest T. UK Renal Registry 13th Annual Report (December 2010): Chapter 1: UK RRT incidence in 2009: national and centre-specific analyses. Nephron Clin Pract. 2011;119(Suppl 2):c1-25.
58. Steenkamp R, Castledine C, Feest T, Fogarty D. UK Renal Registry 13th Annual Report (December 2010): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses. Nephron Clin Pract. 2011;119(Suppl 2):c27-52.
59. NHS blood and transplant. activity report 2012/2013. Transplant Activity in the UK http://www.organdonation.nhs.uk/statistics/transplant-activity-report/ current-activity-reports/ukt/activity-report-2012-13.pdf. Accessed Dec 2013.
60. NHS Kidney Care. Frequently asked questions. payment by results (PbR) - Renal dialysis. Feb 2011. Available from http://webarchive.nationalarchives.gov. uk/20130504185629/http://kidneycare.nhs.uk/resources/?dispFolder=503#. Accessed Jan 2014.
61. Rao A, Gilg J, Williams A. UK Renal Registry 16th Annual Report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: National and Centre-specific Analyses. Available from: http://www.renalreg.com/Report-Area/Report%202013/10-Chap-10.pdf. Accessed May 2014.
62. Department of Health. NHS Reference costs 2010-2011. Available from: https://www.gov.uk/government/publications/2010-11-reference-costs-publication. Accessed Feb 2014.